Recruiting

TruGraf & TRAC

Sponsor:

Transplant Genomics, Inc.

Code:

NCT05335538

Conditions

Kidney Transplant Rejection

Eligibility Criteria

Sex: All

Age: 1 - 18

Healthy Volunteers: Not accepted

Interventions

Patients monitored with TruGraf and TRAC testing

Study Details

Brief summary:

This is a pilot 3 center prospective study of pediatric renal kidney recipients undergoing protocol biopsies examining the performance of the TruGraf gene expression test in children and adolescents.

Conditions

Kidney Transplant Rejection

Study ID

NCT05335538

Start date

Nov 30, 2021

Status verified date

Aug, 2021

Completion date

Mar 1, 2023

Anticipated

Primary completion date

Dec 30, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 1 - 18

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients aged 1-≤ 18 years and recipients of either living or deceased donor transplants Undergoing a protocol biopsy at either 3, 6, 12, 24 or 36 months
  • Serum creatinine at the time of the clinic visit prior to the scheduled biopsy within 30% of a baseline calculated as the mean of the recipient's last 3 serum creatinine levels
  • Serum creatinine level at the time of protocol biopsy ≤ 1.7 mg/dl.
  • Patient receiving immunosuppression with a calcineurin inhibitor (either tacrolimus or cyclosporine) and/or an antimetabolite (either mycophenolate mofetil, mycophenolic acid EC or azathioprine) and/or an mTOR inhibitor (either sirolimus or everolimus) and/or corticosteroids.
  • Absence of any systemic or urinary bacterial, viral or fungal infection
  • Absence of significant BK viremia (as determined by the laboratory where the determination is run) at the time of the last clinical determination and at the time of the protocol biopsy
  • Parents or guardians are capable of reading and understanding the Informed Consent document and willing to participate; if appropriate, patient is also able to understand the Informed Consent. If patient is older than 13 years, patient should be able to give Assent as written on Assent Form.
  • For females of child-bearing age, a negative pregnancy test within 6 weeks of the protocol biopsy.

Exclusion Criteria:

  • Refusal to undergo clinical standard-of-care protocol biopsy by either parent/guardian or patient.
  • Inability to obtain adequate tissue on protocol biopsy
  • Current participation in another interventional research study; patients who have completed the drug in another interventional study are eligible if they meet all other inclusion criteria.
  • Serum creatinine at the clinic visit prior to the biopsy is > 30% of a baseline calculated as the mean of the recipient's last 3 serum creatinine levels.
  • Serum creatinine at the time of the protocol biopsy ≥ 1.8 mg/dl. If the patient had a baseline < 1.8, and the creatinine on the day of biopsy is ≥ 1.8, at the discretion of the PI, the patient will be instructed to hydrate for 4 days and a serum creatinine will be obtained at that time. This is standard clinical practice. If the creatinine returns to the baseline (i.e., ≤ 30%) range, the patient will be classified as having stable renal function, while if the patient's serum creatinine does not return to the ≤ 30% range, he/she will be classified as having renal dysfunction
  • Patients who, in the estimation of the investigator, are undergoing "for-cause" biopsies.
  • Presence of any current and active bacterial, viral or fungal infection
  • Presence of BK viremia judged to be significant by the site PI.
  • Presence of BK nephropathy
  • History of PTLD or malignancy
  • Parents / guardians do not understand Informed Consent and / or are unwilling to participate; patient, if of appropriate age, is unwilling to participate
  • Patients manifesting recurrent disease in their transplant (such as FSGS/nephrotic syndrome, C3 Glomeruopathy, MPGN, hyperoxaluria)
  • Abnormal proteinuria as determined by a urinary protein: creatinine ratio of >1.
  • Recipients of multi-organ transplants.

Study Design

Enrollment

75 participants

Anticipated

Interventions and Outcome Measures

Interventions

Patients monitored with TruGraf and TRAC testing

This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.

Primary outcome measure

  • Concordance of Biomarkers with protocol biopsy [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Cortney Miller, PhD

5107753326cortneymiller@eurofins-tgi.com

Isioma Agboli, MD

15107678609isiomaagboli@eurofins-tgi.com

Locations

The University of Alabama at Birmingham

Recruiting

Birmingham, Alabama, United States, 35294

Contacts

Michael Seifert, MD

mseifert@peds.uab.edu

UCLA Mattel Children's Hospital

Recruiting

Los Angeles, California, United States, 90095

Contacts

Robert Ettenger, MD

REttenger@mednet.ucla.edu

British Columbia Children's Hospital

Recruiting

Vancouver, Canada

Contacts

Tom Blydt-Hansen, MD

tom.blydthansen@cw.bc.ca

More Information

Sponsor

Transplant Genomics, Inc.

Last update posted

Apr 19, 2022

Last verified

Aug, 2021

Keywords

  • Biomarkers
  • Subclinical Rejection
  • Biopsy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Transplant Genomics, Inc. on 2022-04-19.